Archives
-
AO/PI Staining Solution: Evidence and Uses
2026-10-08
AO/PI Staining Solution uses two fluorescent DNA dyes to support conceptual live dead cell discrimination through membrane integrity. This overview places the assay in the context of diabetic nephropathy research, including the 2025 Phytomedicine study of phillygenin, while separating supplier claims from published evidence. It explains what AO/PI readouts can contribute to cell viability research, how they compare conceptually with trypan blue, and why membrane integrity alone cannot establish apoptosis, therapeutic efficacy, or a molecular mechanism.
-
CLCC1 and Herpesvirus Nuclear Egress
2026-10-07
A 2024 bioRxiv preprint identifies CLCC1 as a host factor required for the membrane-fusion stage of herpesvirus nuclear egress, addressing a long-standing gap between viral budding and capsid release. The findings connect viral nuclear egress with nuclear pore complex insertion and suggest an ancient membrane-remodeling mechanism, although the work remains unreviewed and does not yet establish a direct molecular fusion reaction.
-
Grazoprevir Hydrate: Evidence Beyond Efficacy
2026-10-07
Grazoprevir hydrate, also known as MK-5172 hydrate, is examined through mechanism, genotype context, pharmacokinetics, and evidence quality. This article explains how to interpret hepatitis C virus replication inhibition findings without conflating assay potency with clinical benefit.
-
Low-Concentration Chlorhexidine Against E. faecalis
2026-10-06
Sebbane and colleagues examine how low chlorhexidine concentrations affect Enterococcus faecalis through coordinated antibacterial, membrane, structural, biofilm, and gene-expression outcomes. The study’s main contribution is a multi-level mechanistic framework showing that sublethal exposure is associated with membrane damage, reduced biofilm organization, and altered expression of virulence- and stress-related genes, while its in vitro design limits direct clinical translation.
-
DIDS in Cancer Biology: Evidence and Limits
2026-10-06
DIDS is a broadly acting anion transport inhibitor used as a pharmacological tool in studies of chloride transport, mitochondrial membrane biology, vascular physiology, sensory channels, and cancer. This overview examines how DIDS appears in research on prometastatic states, especially the Cell Reports study linking near-death survival to ER stress, cellular reprogramming, and cytokine signaling. It distinguishes reported findings from interpretation and explains why DIDS-associated phenotypes should not be treated as proof of a single chloride-channel mechanism or as evidence of clinical utility.
-
Q-VD(OMe)-OPh in Apoptosis Research: Evidence and Limits
2026-10-05
Q-VD(OMe)-OPh is a broad-spectrum caspase inhibitor used as a mechanistic tool in programmed-cell-death research. This overview distinguishes supplier-described properties from primary evidence, with particular attention to a 2023 colorectal cancer study that included Q-VD-OPh while investigating ferroptosis, autophagy and apoptosis in cetuximab-resistant models.
-
Cryptosporidium AdhE: Imidazole Inhibition Explained
2026-10-05
A 2024 study characterized the bacterial-type bifunctional enzyme CpAdhE in Cryptosporidium parvum and used it as a starting point for chemical screening. Antifungal imidazoles inhibited the enzyme at lower-micromolar concentrations and also reduced parasite growth in vitro, supporting CpAdhE as a researchable but not yet clinically validated antiparasitic target.
-
BH3 Mimetics and Apoptotic Sensitivity in Glioblastoma
2026-10-04
Koessinger and colleagues show that glioblastoma depends on anti-apoptotic BCL-xL and MCL-1 activity, particularly in stem-like tumour cell populations. Their preclinical evidence supports a model in which coordinated targeting of these survival dependencies can expose apoptotic vulnerability, while also highlighting the limits of translating model-specific responses into clinical treatment.
-
RNase R and the Translational Future of circRNA
2026-10-03
A source-grounded perspective on how Ribonuclease R supports circular RNA enrichment, how the circHIF1A/miR-486-5p/GRHL2 study informs translational strategy in lung adenocarcinoma, and why nuclease resistance should be treated as one layer of evidence rather than definitive proof of circularity.
-
DIDS as a Causal Probe in Tumor Biology
2026-10-02
DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is more than a chloride-channel research reagent. This article presents a causal assay framework for separating ion-transport effects from apoptosis-rescue artifacts when studying near-death tumor states and prometastatic phenotypes.
-
Gepotidacin vs Nitrofurantoin in Uncomplicated UTI
2026-10-01
The EAGLE-2 and EAGLE-3 phase 3 trials evaluated gepotidacin, a first-in-class oral antibiotic with a distinct bacterial topoisomerase mechanism, against nitrofurantoin for uncomplicated urinary tract infection. Gepotidacin met the prespecified non-inferiority criterion in both trials and was superior in EAGLE-3, supporting its potential as an oral option while highlighting the importance of endpoint definition, interim stopping, and population selection.
-
Alfuzosin HCl: From Receptor Biology to Translation
2026-10-01
A mechanistic and translational roadmap for using Alfuzosin HCl in benign prostatic hyperplasia research, integrating α1-adrenergic pharmacology, analytical validation, gastroretentive formulation design, and clinical relevance.
-
ABT-263 (Navitoclax) Workflow Guide
2026-09-30
This practical guide explains how to prepare, store, and evaluate ABT-263 (Navitoclax) in apoptosis assays and cancer biology workflows when no directly matched paper evidence is available. It is intended for research use only and should not be used to establish clinical dosing, diagnostic procedures, or medical treatment conditions.
-
Chemistry of Silybin: Structure, Derivatives, and Uses
2026-09-30
Křen and colleagues provide a comprehensive chemistry-focused account of silybin, clarifying its stereochemistry, isolation, resolution, synthesis, and derivative chemistry through the literature available from 1959 to 2013. The review’s main practical value is its distinction between isolated silybin and the chemically complex silymarin mixture, a distinction that remains important when designing reproducible biological assays.
-
EZ Cap™ OVA mRNA: Delivery & Assay Workflows
2026-09-29
EZ Cap™ OVA mRNA provides a defined Ovalbumin mRNA input for antigen-expression assays, immune-response studies, airway models, and vaccine development research. This guide connects its Cap 1 and poly(A) design with practical delivery optimization and the low-inflammation LNP strategy reported in recent preclinical work.